EGFR and non-small cell lung carcinoma: Marcelo et al. analyzed data from more than 4000 driver-positive NSCLC patients, observing that patients with classic EGFR mutation and HER2 mutations who were treated with ICIs had the shortest PFS (1.8 and 1.9 months, respectively) [36].